Published in MAbs on January 01, 2015
Pre-existing Antibody: Biotherapeutic Modality-Based Review. AAPS J (2016) 0.77
An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques. Clin Vaccine Immunol (2016) 0.76
Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies. J Immunol Res (2016) 0.75
Preexisting Antibodies to an F(ab')2 Antibody Therapeutic and Novel Method for Immunogenicity Assessment. J Immunol Res (2016) 0.75
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. J Immunol Res (2016) 0.75
Evading pre-existing anti-hinge antibody binding by hinge engineering. MAbs (2016) 0.75
CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6(+) cells in an experimental suction blister. Br J Clin Pharmacol (2017) 0.75
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. Br J Clin Pharmacol (2017) 0.75
Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay. PLoS One (2017) 0.75
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Anti-gamma-globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang (1963) 4.32
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.26
A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med (1984) 3.07
The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J Allergy Clin Immunol (2011) 2.90
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA (2011) 2.73
The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut (2010) 2.61
The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol (2005) 2.55
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis (2012) 2.29
The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis (2014) 2.25
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis (2008) 2.21
Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther (2013) 2.21
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis (2004) 2.18
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis (2012) 2.06
Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J Immunol Methods (2000) 2.05
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal (2008) 2.05
IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 1.95
Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs (2010) 1.89
The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs (2010) 1.86
Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem (2006) 1.84
Biophysical properties of human antibody variable domains. J Mol Biol (2003) 1.80
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis (2004) 1.80
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77
Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol (2008) 1.75
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis (2011) 1.68
ANTIBODY TO HEREDITARY HUMAN GAMMA-GLOBULIN (GM) FACTOR RESULTING FROM MATERNAL-FETAL INCOMPATIBILITY. Science (1964) 1.57
Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen-antibody complexes. Eur J Immunol (1978) 1.57
Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) (2007) 1.53
Complement is activated by IgG hexamers assembled at the cell surface. Science (2014) 1.52
When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen. Clin Chem (1999) 1.51
Immunogenic and antigenic epitopes of immunoglobulins. XVII--Monoclonal antibodies reactive with common and restricted idiotopes to the heavy chain of human rheumatoid factors. Rheumatol Int (1986) 1.47
Human anti-mouse antibodies. Arch Pathol Lab Med (2000) 1.45
Are lymphocytes concerned with our definition of idiotypes? Immunol Today (1993) 1.44
Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol (2011) 1.40
Thrombocytopenia after abciximab use results from different mechanisms. Thromb Haemost (2010) 1.39
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis (2012) 1.35
Rheumatoid factor revisited. Curr Opin Rheumatol (2004) 1.33
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol (2013) 1.32
The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res (2013) 1.24
Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol (2008) 1.23
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J (2014) 1.22
Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med (1986) 1.21
The immunoglobulin heavy chain locus: genetic variation, missing data, and implications for human disease. Genes Immun (2012) 1.19
A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging (2004) 1.14
Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? MAbs (2010) 1.12
IgE production to α-gal is accompanied by elevated levels of specific IgG1 antibodies and low amounts of IgE to blood group B. PLoS One (2013) 1.11
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics (2009) 1.11
A novel strategy to reduce the immunogenicity of biological therapies. J Immunol (2010) 1.10
Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol (2011) 1.10
Elimination of the immunogenicity of therapeutic antibodies. J Immunol (1999) 1.08
The immunochemistry of sandwich ELISAs--VI. Greater than 90% of monoclonal and 75% of polyclonal anti-fluorescyl capture antibodies (CAbs) are denatured by passive adsorption. Mol Immunol (1993) 1.06
Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp Clin Immunogenet (1989) 1.05
Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J Immunol Methods (2010) 1.05
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer (2011) 1.04
Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J Immunol (2009) 1.02
Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum (2013) 1.02
Polymorphism and utilization of human VH Genes. Ann N Y Acad Sci (1995) 1.00
The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol (1995) 0.99
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler (2012) 0.97
Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. J Immunol Methods (2012) 0.97
Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. Anal Biochem (2009) 0.97
Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum (1988) 0.97
Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol (2008) 0.95
The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science (1986) 0.95
Evidence for immune complexes containing antibody to the pepsin site of IgG in rheumatoid synovial fluids. Clin Exp Immunol (1971) 0.95
Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol (2009) 0.94
Antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors. The C gamma 2-C gamma 3 interface region contains the major determinants. J Immunol (1988) 0.94
Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods (2011) 0.94
IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs (2010) 0.93
Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother (2003) 0.92
Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol (2012) 0.92
Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem (2014) 0.90
Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheumatol (2014) 0.90
Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J Biol Chem (2014) 0.89
Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis. Clin Chem Lab Med (2006) 0.89
Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8. Scand J Immunol (1999) 0.88
The natural human IgG anti-F(ab')2 antibody recognizes a conformational IgG1 hinge epitope. J Immunol (1995) 0.88
Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther (2010) 0.87
The generative grammar of the immune system. Science (1985) 0.87
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today (2014) 0.87
Rheumatoid factors: what's new? Rheumatology (Oxford) (2006) 0.87
Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol (2013) 0.86
Prevalence of human anti-mouse antibodies (HAMAs) in routine examinations. Clin Chim Acta (2009) 0.86
Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. J Immunol (1995) 0.86
Final results of the ReoPro readministration registry. Am J Cardiol (2004) 0.85
The origins, specificity, and potential biological relevance of human anti-IgG hinge autoantibodies. ScientificWorldJournal (2011) 0.84
Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis (2013) 0.84
Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. Mol Immunol (2012) 0.83
A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. MAbs (2014) 0.83
A rheumatoid factor paradox: inhibition of rituximab effector function. Arthritis Res Ther (2013) 0.82
Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody. J Pharm Biomed Anal (2011) 0.82
Interactions between immunoglobulin G molecules. Immunol Lett (2010) 0.81
Immobilization of antibodies on ultraflat polystyrene surfaces. Clin Chem (2000) 0.80
The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site. Genes Immun (2011) 0.80
Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin Drug Metab Toxicol (2014) 0.79
Therapy: Immunogenicity of biologic therapies-we need tolerance. Nat Rev Rheumatol (2010) 0.79
Prediction of successful allograft rejection retreatment with OKT3. Transplantation (1992) 0.79
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis (2012) 1.35
Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol (2011) 1.34
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol (2013) 1.32
Differential effect of drug interference in immunogenicity assays. J Immunol Methods (2011) 1.17
Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol (2011) 1.10
Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One (2011) 1.07
A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood (2013) 1.03
Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis (2013) 0.99
Crystal structure of the human IgG4 C(H)3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange. Mol Immunol (2012) 0.98
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler (2012) 0.97
IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol (2012) 0.96
IgG4-Related Fibrotic Diseases from an Immunological Perspective: Regulators out of Control? Int J Rheumatol (2012) 0.95
Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol (2012) 0.92
Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation. Arthritis Rheumatol (2014) 0.90
A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study. Anal Bioanal Chem (2013) 0.84
Therapy: Immunogenicity of biologic therapies-we need tolerance. Nat Rev Rheumatol (2010) 0.79
Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. Rheumatology (Oxford) (2012) 0.79
Haplotypes of FcγRIIa and FcγRIIIb polymorphic variants influence IgG-mediated responses in neutrophils. J Immunol (2014) 0.79
Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 0.78
Use of a human recombinant immunoglobulin G1 CH3 domain as a probe for detecting alternatively folded human IgG in intravenous Ig products. J Pharm Sci (2011) 0.76
Probing bis-ANS binding sites of different affinity on aggregated IgG by steady-state fluorescence, time-resolved fluorescence and isothermal titration calorimetry. J Pharm Sci (2010) 0.76
Drug interference in immunogenicity assays depends on valency. J Pharm Biomed Anal (2013) 0.76
The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab. J Immunotoxicol (2013) 0.76
Immunogenicity of therapeutic antibodies: monitoring anti-drug antibodies in a clinical context. Ther Drug Monit (2017) 0.76
Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis with Biological Agents. Ther Drug Monit (2017) 0.76
Reply to Ruiz-Argüello et al.: Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med (2013) 0.75
[TNF inhibitors: the role of drug levels]. Ned Tijdschr Geneeskd (2014) 0.75
Preventing adsorption of immunoglobulin G to solid surfaces using poloxamer 407 eliminates artifactual stimulation of neutrophils. J Immunol Methods (2013) 0.75